Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant

European Journal of Clinical Pharmacology
E LunellM Andersson

Abstract

The relative bioavailability of nicotine from a nasal spray was assessed in 15 smokers suffering a common cold and rhinitis according to generally accepted criteria. The patients were given a single dose of 2 mg nicotine from the nasal spray with and without concurrent administration of a nasal vasoconstrictor decongestant, xylometazoline, in randomised order. Control session measurements were made in the disease-free state. Applying strict bioequivalence criteria, we found that common cold/rhinitis slightly reduced the bioavailability of nicotine, both in its rate and extent; the geometric mean of the ratio of Cmax, AUC and tmax were 0.81, 0.93 and 1.36, respectively. The nasal vasoconstrictor, xylometazoline, normalised the extent of the bioavailability of nicotine, but further prolonged the time for absorption to almost twice that measured in the disease-free state, increasing the tmax ratio to 1.72. The results suggest that a minor proportion of people stopping smoking with the help of a nicotine nasal spray may experience a minor reduction in the effect of the spray during common cold/rhinitis. However, the nicotine self-titration behaviour found with most smoking cessation products (except the nicotine patch) will automat...Continue Reading

References

Sep 1, 1992·Clinical Pharmacokinetics·N G Schneider
Jan 1, 1991·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·C G PerssonC Svensson
Sep 1, 1987·British Journal of Addiction·M J JarvisC Feyerabend
Mar 1, 1980·Lancet·M A RussellC Feyerabend
Feb 26, 1983·British Medical Journal·M A RussellO Fernö

❮ Previous
Next ❯

Citations

Feb 1, 2013·Drug Delivery and Translational Research·Julie D Suman
Sep 3, 2008·Pharmacology, Biochemistry, and Behavior·Saul ShiffmanTommy Chau
Oct 13, 2009·The Journal of the Association of Nurses in AIDS Care : JANAC·María José Míguez-BurbanoRobert Duncan
Apr 1, 1996·Clinical Pharmacology and Therapeutics·L MolanderF Kuylenstierna
Apr 12, 2001·Clinical Otolaryngology and Allied Sciences·R J SoaneL Illum
Jan 11, 2018·Therapeutic Advances in Drug Safety·Rachael Rzasa Lynn, J L Galinkin
Oct 30, 2010·The International Journal of Neuropsychopharmacology·Irina EsterlisKelly P Cosgrove

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute viral rhinopharyngitis

Acute viral rhinopharyngitis, also known as "common cold", is an acute, self-limiting viral infection of the upper respiratory tract involving the nose, sinuses, pharynx and larynx. Discover the latest research on acute viral rhinopharyngitis here.